General description

A cell-permeable salicylidene compound that is shown to directly target Ireα1 and disrupt Ire1-XBP1 (X-box binding protein) unfolded protein response (UPR) pathway in RPMI8226 multiple myeloma (MM) cells. Selectively inhibits ER stress-initiated endonuclease activity of Ire1 and blocks XPB1 mRNA splicing in MM cells at 60 µM and XBP1 activity in transgenic XBP1-luc mice (bortezomib 1mg/kg and 60 mg/kg of STF-083010, i.p.). Displays preferential cytotoxicity towards CD138+ cells over B, T and NK cells and antitumor properties.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Lerner, A.G., et al. 2012 Cell Metabolism16, 250.Papandreou, I., et al. 2010. Blood117, )1311.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Unstable in solution; reconstitute just prior to use.

Warning

Toxicity: Regulatory Review (Z)